MaxCyte, Inc. (LON:MXCT - Get Free Report) shares reached a new 52-week low during trading on Thursday . The company traded as low as GBX 200 ($2.56) and last traded at GBX 205.68 ($2.63), with a volume of 26796 shares changing hands. The stock had previously closed at GBX 213 ($2.72).
MaxCyte Stock Up 4.0 %
The firm has a 50-day moving average of GBX 276.11 and a two-hundred day moving average of GBX 298.64. The company has a quick ratio of 14.38, a current ratio of 9.81 and a debt-to-equity ratio of 8.59. The company has a market capitalization of £260.05 million, a PE ratio of -7.22 and a beta of 1.13.
About MaxCyte
(
Get Free Report)
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Featured Stories
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
